TMZ is well tolerated and provides a substantial rate of response in LGOT. Chromosome 1p loss is correlated with radiographic response and could be a helpful marker for guiding therapeutic decision making in LGOT.
Objective:To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy. Methods: Adult These tumors share an invasive and malignant potential. Gross total surgical resection, whenever possible, is recommended. Radiotherapy is considered as a postoperative standard treatment for LGG, although the optimal timing of this treatment (i.e., immediate vs at progression) remains debatable. 3,4 We and others have recently provided some evidence based on small studies that temozolomide (TMZ), an oral alkylating agent, may represent an interesting alternative option as a primary treatment after surgery in diffuse LGG. [5][6][7] We have reported preliminary results suggesting that chromosome 1p deletion is correlated with radiographic response of LGG to TMZ and might represent a helpful molecular tumor marker for guiding therapeutic decision-making. 6 In the present study we report additional data from an extended series of patients with longer follow-up confirming the efficacy of TMZ in progressive LGG and the predictive value of 1p/19q loss both in terms of prognosis and chemosensitivity.From APHP, Service de
Background The likelihood that health‐related quality of life (HRQoL) could depend on factors other than clinical data increases with the duration of follow‐up since diagnosis. The aim of this study was to identify determinants of long‐term HRQoL in women with cervical, endometrial, and ovarian cancer. Secondary objectives were to describe their living conditions (sexual function, psychological distress, social and professional reinsertion). Materials and Methods In a cross‐sectional survey, women diagnosed with cervical, endometrial, and ovarian cancers from 2006 to 2013 were selected through the French gynecological cancers registry of Côte d'Or. Validated questionnaires exploring HRQoL (short‐form health survey; SF‐12), anxiety and depression (Hospital Anxiety and Depression Scale), social support (Sarason's Social Support Questionnaire), sexual function (Female Sexual Function Index), and living conditions (EPICES questionnaire) were used to assess HRQoL and its determinants. Social and professional reinsertion were also investigated using study‐specific questionnaires. Determinants of HRQoL were identified using a multivariable mixed‐regression model for each composite score of the SF‐12. Results In total, 195 gynecological cancer survivors participated in the survey. HRQoL was deteriorated for almost all the SF‐12 dimensions. The main determinants of poor HRQoL were comorbidities, deprivation, lack of availability and satisfaction with social support, and psychological outcomes. Thirty‐four percent of survivors of gynecological cancer reported a negative impact of cancer on their work, and 73% reported an impaired ability to work after treatment. Conclusions Long‐term HRQoL of survivors of gynecological cancer is not impacted by stage of disease. Specific interventions should focus on issues that promote social and professional reintegration and improve HRQoL. Implications for Practice This study shows that women with gynecological cancer have problems related to work and sexual dysfunction, even 5 years after diagnosis. The results of this study will help improve clinicians’ awareness of the factors affecting the lives of gynecological cancer survivors, even long after diagnosis and treatment. They will also highlight for clinicians the areas that are of importance to gynecological cancer survivors, making it possible to guide management of these patients with a view to preventing deteriorated health‐related quality of life after treatment. For the health authorities, the results of this study underline that more than 5 years after gynecological cancer, the initial stage of disease no longer affects quality of life, but there is a clear need for actions targeting socio‐professional reintegration of survivors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.